Metformin-induced Changes of the Gut Microbiota in Patients with Type 2 Diabetes Mellitus: Results from a Prospective Cohort Study

Overview

Journal Endocrine

Specialty Endocrinology

Date 2024 May 18

PMID 38761345

Authors

Yuting Gao

Tianyi Zhao

Na Lv

Shixuan Liu

Tao Yuan

Yong Fu

Weigang Zhao

Baoli Zhu

Affiliations

Soon will be listed here.

Abstract

Background: The influence of the microbiota on hypoglycemic agents is becoming more apparent. The effects of metformin, a primary anti-diabetes drug, on gut microbiota are still not fully understood.

Research Design And Methods: This prospective cohort study aims to investigate the longitudinal effects of metformin on the gut microbiota of 25 treatment-naïve diabetes patients, each receiving a daily dose of 1500 mg. Microbiota compositions were analyzed at baseline, and at 1, 3, and 6 months of medication using 16S rRNA gene sequencing.

Results: Prior to the 3-month period of metformin treatment, significant improvements were noted in body mass index (BMI) and glycemic-related parameters, such as fasting blood glucose (FPG) and hemoglobin A1c (HbA1c), alongside homeostasis model assessment indices of insulin resistance (HOMA-IR). At the 3-month mark of medication, a significant reduction in the α-diversity of the gut microbiota was noted, while β-diversity exhibited no marked variances throughout the treatment duration. The Firmicutes to Bacteroidetes ratio. markedly decreased. Metformin treatment consistently increased Escherichia-Shigella and decreased Romboutsia, while Pseudomonas decreased at 3 months. Fuzzy c-means clustering identified three longitudinal trajectory clusters for microbial fluctuations: (i) genera temporarily changing, (ii) genera continuing to decrease (Bacteroides), and (iii) genera continuing to increase(Lachnospiraceae ND3007 group, [Eubacterium] xylanophilum group, Romboutsia, Faecalibacterium and Ruminococcaceae UCG-014). The correlation matrix revealed associations between specific fecal taxa and metformin-related clinical parameters HbA1c, FPG, Uric Acid (UA), high-density lipoproteincholesterol (HDL-C), alanine aminotransferase (ALT), hypersensitive C-reactive protein (hs-CRP), triglyceride (TG) (P < 0.05). Metacyc database showed that metformin significantly altered 17 functional pathways. Amino acid metabolism pathways such as isoleucine biosynthesis predominated in the post-treatment group.

Conclusions: Metformin's role in glucose metabolism regulation may primarily involve specific alterations in certain gut microbial species rather than an overall increase in microbial species diversity. This may suggest gut microbiota targets in future studies on metabolic abnormalities caused by metformin.

Citing Articles

Evaluating the Effects of Sugar Shift Symbiotic on Microbiome Composition and LPS Regulation: A Double-Blind, Placebo-Controlled Study.

Garcia G, Soto J, Netherland Jr M, Hasan N, Buchaca E, Martinez D Microorganisms. 2025; 12(12.

PMID: 39770729 PMC: 11678924. DOI: 10.3390/microorganisms12122525.

References

Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe K . Pathophysiology of Type 2 Diabetes Mellitus. Int J Mol Sci. 2020; 21(17). PMC: 7503727. DOI: 10.3390/ijms21176275. View

Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan B . IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2021; 183:109119. PMC: 11057359. DOI: 10.1016/j.diabres.2021.109119. View

Tilg H, Moschen A . Microbiota and diabetes: an evolving relationship. Gut. 2014; 63(9):1513-21. DOI: 10.1136/gutjnl-2014-306928. View

Cunningham A, Stephens J, Harris D . Gut microbiota influence in type 2 diabetes mellitus (T2DM). Gut Pathog. 2021; 13(1):50. PMC: 8343927. DOI: 10.1186/s13099-021-00446-0. View

Foretz M, Guigas B, Viollet B . Metformin: update on mechanisms of action and repurposing potential. Nat Rev Endocrinol. 2023; 19(8):460-476. PMC: 10153049. DOI: 10.1038/s41574-023-00833-4. View

McCreight L, Bailey C, Pearson E . Metformin and the gastrointestinal tract. Diabetologia. 2016; 59(3):426-35. PMC: 4742508. DOI: 10.1007/s00125-015-3844-9. View

Bailey C, Wilcock C, Scarpello J . Metformin and the intestine. Diabetologia. 2008; 51(8):1552-3. DOI: 10.1007/s00125-008-1053-5. View

Bonora E, Cigolini M, Bosello O, Zancanaro C, Capretti L, Zavaroni I . Lack of effect of intravenous metformin on plasma concentrations of glucose, insulin, C-peptide, glucagon and growth hormone in non-diabetic subjects. Curr Med Res Opin. 1984; 9(1):47-51. DOI: 10.1185/03007998409109558. View

Buse J, DeFronzo R, Rosenstock J, Kim T, Burns C, Skare S . The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies. Diabetes Care. 2015; 39(2):198-205. DOI: 10.2337/dc15-0488. View

10.

Shin N, Lee J, Lee H, Kim M, Whon T, Lee M . An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut. 2013; 63(5):727-35. DOI: 10.1136/gutjnl-2012-303839. View

11.

Mueller N, Differding M, Zhang M, Maruthur N, Juraschek S, Miller 3rd E . Metformin Affects Gut Microbiome Composition and Function and Circulating Short-Chain Fatty Acids: A Randomized Trial. Diabetes Care. 2021; 44(7):1462-1471. PMC: 8323185. DOI: 10.2337/dc20-2257. View

12.

de la Cuesta-Zuluaga J, Mueller N, Corrales-Agudelo V, Velasquez-Mejia E, Carmona J, Abad J . Metformin Is Associated With Higher Relative Abundance of Mucin-Degrading Akkermansia muciniphila and Several Short-Chain Fatty Acid-Producing Microbiota in the Gut. Diabetes Care. 2016; 40(1):54-62. DOI: 10.2337/dc16-1324. View

13.

Forslund K, Hildebrand F, Nielsen T, Falony G, Le Chatelier E, Sunagawa S . Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature. 2015; 528(7581):262-266. PMC: 4681099. DOI: 10.1038/nature15766. View

14.

Zhang F, Wang M, Yang J, Xu Q, Liang C, Chen B . Response of gut microbiota in type 2 diabetes to hypoglycemic agents. Endocrine. 2019; 66(3):485-493. DOI: 10.1007/s12020-019-02041-5. View

15.

Elbere I, Silamikelis I, Dindune I, Kalnina I, Briviba M, Ustinova M . Baseline gut microbiome composition predicts metformin therapy short-term efficacy in newly diagnosed type 2 diabetes patients. PLoS One. 2020; 15(10):e0241338. PMC: 7598494. DOI: 10.1371/journal.pone.0241338. View

16.

Sun L, Xie C, Wang G, Wu Y, Wu Q, Wang X . Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nat Med. 2018; 24(12):1919-1929. PMC: 6479226. DOI: 10.1038/s41591-018-0222-4. View

17.

Nakajima H, Takewaki F, Hashimoto Y, Kajiyama S, Majima S, Okada H . The Effects of Metformin on the Gut Microbiota of Patients with Type 2 Diabetes: A Two-Center, Quasi-Experimental Study. Life (Basel). 2020; 10(9). PMC: 7555986. DOI: 10.3390/life10090195. View

18.

Napolitano A, Miller S, Nicholls A, Baker D, Van Horn S, Thomas E . Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus. PLoS One. 2014; 9(7):e100778. PMC: 4079657. DOI: 10.1371/journal.pone.0100778. View

19.

Magoc T, Salzberg S . FLASH: fast length adjustment of short reads to improve genome assemblies. Bioinformatics. 2011; 27(21):2957-63. PMC: 3198573. DOI: 10.1093/bioinformatics/btr507. View

20.

Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett W . Metagenomic biomarker discovery and explanation. Genome Biol. 2011; 12(6):R60. PMC: 3218848. DOI: 10.1186/gb-2011-12-6-r60. View